The universe of cancer stocks endured several challenges
during the quarter, extending its losses subsequent to the ASCO meeting in
early June. The median return of the group now is -9.9% on
the year thus far and the average is +4.7% (demonstrating the skew that
attracts people in the first place to the sector). The AMEX Biotech Index [BTK]
is up about 9% on the year. The lists
below, with data from StockVal, are
comprised of domestic companies primarily.
The total universe has...
The lists below, with data from StockVal, are comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week. If the reader believes that there are erroneous inclusions or exclusions, feel free to let me know.
There were even fewer outliers in this holiday-shortened week, with 4 double-digit gainers and just one double-digit...
Alan Brochstein, CFA submits:
After plunging in the weeks following ASCO, cancer stocks were stabilized this week.
The lists below, with data from StockVal, are comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.
There were much fewer outliers this week, with 5 double-digit gainers and just three double-digit decliners. The median return of -0.7% trailed the S&P 500 return, which was flat, but the average of 0.1% was in...
Alan Brochstein, CFA submits:
After plunging in the week following ASCO and then underperforming the following week, cancer stocks were hammered yet again.
The list below, with data from StockVal, is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.
The 14 double-digit declines exceeded the 12 that plunged immediately following the ASCO meeting, with just a single double-digit gainer. The median return of -4.2% and the average...
Alan Brochstein, CFA submits:
After plunging in the week following ASCO, cancer-related stocks merely underperformed this week.
The list below, with data from StockVal, is comprised of domestic companies primarily with market caps in excess of $50mm, ranked by the return this past week.
The number of double-digit declines decreased from 12 to just 4, but there were no double-digit gainers. The median return of 0.0 and the average return of -0.3 trailed the S&P 500 significantly (-1.6% and -2%...
Alan Brochstein, CFA submits:
Cancer-related stocks soared during the holiday-shortened week as presentations began on June 1st at the ASCO annual meeting in Chicago.
Last week?s big winner, Bioenvision (BIVN), received an offer from partner Genzyme (GENZ) at a disappointing premium but well ahead of multi-year lows reached in early May.
The list below is comprised of domestic companies primarily with market caps in excess of $50mm, ranked...
Alan Brochstein, CFA submits:
Later this week, the big event of the year for companies trying to treat cancer takes place in Chicago: the American Society of Clinical Oncology?s Annual Meeting. Not surprisingly, the universe of cancer stocks performed well in a rather lackluster week for the market.
I recently created a list of companies with market capitalization in excess of $50mm at the beginning of May that derive a significant amount of their market value from cancer-related pursuits. ...
www.bharatbook.com included a new report on ?Immunicon Corporation Product Pipeline Analysis? into its market report catalogue for reselling. This report is an insightful source for data, analysis ...
Immunicon Corporation (Immunicon) is engaged in the development and commercialization of research and diagnostic products that are used in molecular research and rare cell analysis with main focus ...
Stock News 
